

**ATTACHMENT H**

**FEB 11 2002**

**SUMMARY OF SAFETY AND EFFECTIVENESS**

Pursuant to §513(i)(3)(A) of the Food, Drug, and Cosmetic Act, Boston Scientific Corporation is required to submit with this Premarket Notification either an "... adequate summary of any information respecting safety and effectiveness or state that such information will be made available upon request of any person." Boston Scientific Corporation chooses to submit a summary of information respecting safety and effectiveness. According to §513(i)(3)(B), "Any summary under subparagraph (A) respecting a device shall contain detailed information regarding data concerning adverse health effects..."

The summary regarding the adverse health effects of the proposed Back-Up Meier Steerable Guidewire is as follows:

**Trade Name:** Back-Up Meier Steerable Guidewire

**Manufacturer:** Boston Scientific Corporation  
8600 NW 41<sup>st</sup> Street  
Miami, Florida 33166-3355

**Device Generic Name:** Guidewire

**Classification:** According to Section 13 of the Federal Food, Drug and Cosmetic Act, the device classification is Class II, Performance Standards.

**Predicate Devices:** The following device is referenced in this premarket notification as the predicate device for the Back-Up Meier Steerable Guidewire:

Boston Scientific Corporation -- Back-Up Meier Steerable Guidewire (K011906)

The device mentioned above has been determined substantially equivalent by FDA.

000091

**Device Description:** The proposed Back-Up Meier Steerable Guidewires are intended to facilitate catheter placement and exchange during diagnostic or interventional procedures including AAA endovascular graft procedures. The Back-Up Meier Steerable Guidewires are sterile, single-use wirres and are available in different tip shapes with overall wire lengths of 185cm – 300cm. The distal segment of the wire is radiopaque to aid in visualization of the device under fluoroscopy.

**Indications for Use:** The Back-Up Meier Steerable Guidewire facilitates catheter placement and exchange during diagnostic or interventional procedures including AAA endovascular graft procedures.

**Safety and Performance:** Bench testing and biocompatibility testing were performed to support a determination of substantial equivalence. The results of these tests provide reasonable assurance that the proposed device has been designed and tested to assure conformance to the requirements for its intended use. No new safety or performance issues were raised during the testing regimen.

**Conclusion:** Based on the Indication for Use, technological characteristics and safety and performance testing, the Back-Up Meier Steerable Guidewire has been shown to be safe and effective for its intended use.



Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

FEB 11 2002

Ms. Jennifer Bolton, RAC  
Senior Regulatory Affairs Specialist  
Boston Scientific Corporation  
One Boston Scientific Place  
Natick, MA 01760-1537

Re: K020283

Trade Name: Back-Up Meier Steerable Guidewire  
Regulation Number: 21 CFR 870.1330  
Regulation Name: Wire, Guide, Catheter  
Regulatory Class: Class II (two)  
Product Code: DQX  
Dated: January 25, 2002  
Received: January 28, 2002

Dear Ms. Bolton:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Page 2 - Ms. Jennifer Bolton, RAC

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4646. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>

Sincerely yours,

Handwritten signature of Bram D. Zuckerman in black ink.

Bram D. Zuckerman, M.D.  
Acting Director  
Division of Cardiovascular  
and Respiratory Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

**510(k) Number (if known):** New Application

**Device Name:** Back-Up Meier Steerable Guidewire

**Indications for Use:**

The Back-Up Meier Steerable Guidewire facilitates catheter placement and exchange during diagnostic or interventional procedures including AAA endovascular graft procedures.

**(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED.)**

\_\_\_\_\_  
Concurrence of CDRH, Office of Device Evaluation (ODE)

  
Division of Cardiovascular & Respiratory Devices  
510(k) Number 202083

☒ Prescription Use

OR

☐ Over-The-Counter Use

(Per 21 CFR 801.109)

(Optional Format 1-2-96)